EPHX2 and postmenopausal osteoporosis: By targeting both inflammatory and bone-resorptive pathways without impairing physiological bone remodeling, sEH inhibition emerges as a promising therapeutic strategy for managing bone loss associated with postmenopausal osteoporosis and periodontitis.